Alasdair is the General Counsel of Syncona Investment Management Ltd.
Alasdair leads the Syncona legal team, is part of the leadership team, and supports the Board on all Company Secretary matters.
He has three decades of experience in business law in the life sciences sector. Most recently he was General Counsel EMEA and APAC of Mundipharma and prior to that General Counsel EMEA of Thermo Fisher Scientific Inc., where he helped drive the successful transformation of those businesses. He has worked in senior legal roles in Gilead Sciences Inc., Cambridge Antibody Technology PLC (acquired by AstraZeneca PLC), and Pfizer Inc., after qualifying as a solicitor with Linklaters.
Alasdair has a degree in biological sciences (Immunology) from the University of Edinburgh and an MBA from London Business School.